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Background: Elevated uric acid (UA) is commonly associated with gout and it is also a known cardiovascular
disease risk factor. In contrast to such deleterious effects, UA possesses neuroprotective properties in the brain and
elucidating the molecular mechanisms involved may have significant value regarding the therapeutic treatment of
neurodegenerative disease. However, it is not yet fully established how UA levels are regulated in the brain. In this
study, we investigated the distribution of mouse urate transporter 1 (URAT1) in the brain. URAT1 is a major
reabsorptive urate transporter predominantly found in the kidney.
Methods: Immunohistochemistry of wild type and URAT1 knockout mouse brain using paraffin or frozen sections
and a rabbit polyclonal anti-mouse URAT1 antibody were employed.
Results: Antibody specificity was confirmed by the lack of immunostaining in brain tissue from URAT1 knockout
mice. URAT1 was distributed throughout the ventricular walls of the lateral ventricle, dorsal third ventricle, ventral
third ventricle, aqueduct, and fourth ventricle, but not in the non-ciliated tanycytes in the lower part of the ventral
third ventricle. URAT1 was localized to the apical membrane, including the cilia, of ependymal cells lining the wall
of the ventricles that separates cerebrospinal fluid (CSF) and brain tissue.
Conclusion: In this study, we report that URAT1 is expressed on cilia and the apical surface of ventricular
ependymal cells. This is the first report to demonstrate expression of the urate transporter in ventricular ependymal
cells and thus raises the possibility of a novel urate transport system involving CSF.
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Uric acid (UA) is the end product of purine metabolism in
human and hyperuricemia is a known risk factor for gout,
hypertension, renal disease, and metabolic syndrome [1].
While high levels of UA are considered as a pathogenic
factor, UA also possesses antioxidant properties and epi-
demiological studies have shown that reduced concentra-
tions of UA are linked to neurodegenerative disorders such
as multiple sclerosis, Parkinson’s disease (PD), Alzheimer’s
disease and optic neuritis [2], supporting the potential neu-
roprotective effect of UA. In addition to human epidemio-
logical studies, the neuroprotective effect of UA has also
been identified in cellular and animal models for PD [3-5].* Correspondence: hosoyamd@pharm.teikyo-u.ac.jp
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reproduction in any medium, provided the orPhysiologically, UA concentrations are an order of mag-
nitude lower in cerebral tissue compared to blood UA
levels [6]. Interestingly, studies have reported that CSF
and blood UA levels are correlated [5,7]. Furthermore,
increased plasma and striatum levels of UA have been
detected in rats given intraperitoneal injections of UA [4].
These reports suggest that UA in the brain, and CSF,
might be dependent upon the level of UA in the blood,
while UA could also be synthesized locally in the brain [5].
However, due to a significant lack of information regar-
ding the key molecules involved, the origin of brain UA, or
how UA homeostasis is maintained in brain parenchyma
and CSF, remains largely unknown.
Multiple urate transporters in the kidney are involved in
the regulation of serum UA levels (SUA). Renal urate re-
absorption is mainly mediated by urate transporter 1
(URAT1) on the apical side of the renal proximal tubularl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Glut9) on the basolateral side [8,9]. In addition, the ATP-
binding cassette transporter, sub-family G, member 2
(ABCG2), has been identified as another transporter that
regulates SUA [10-12]. Intriguingly, while the presence of
these transporters in the brain has been demonstrated in
several studies [13-16], detailed spatial information of the
specific localization pattern of these vital transporters is
generally lacking.
In the present study, we investigated the distribution of
URAT1 in mouse brain by immunohistochemical analysis
using an anti-URAT1 antibody [17], the specificity of
which was confirmed using a URAT1 knockout mouse.
Methods
Animals
Male C57BL/6 J mice (Sankyo Laboratories, Tokyo, Japan)
and homozygous URAT1 knockout mice [17] were main-
tained under a 14:10 light cycle with free access to food
and water. For this study, 8–10 mice were used in each
group. All animal experiments were carried out in accor-
dance with the guidelines for animal experimentation in
Teikyo University and the project was approved by the
local committee.
Immunohistochemistry of URAT1 in mouse brain
Nine-week-old C57BL/6 J male mice and URAT1 knock-
out male mice were anesthetized by pentobarbital injec-
tion (50 mg/kg, i.p.) and perfused intra-cardially with 4%
paraformaldehyde in HEPES buffer (30 mM HEPES,
100 mM NaCl, 2 mM CaCl2, pH 7.5). Brains were re-
moved and post-fixed overnight (for paraffin embedding)
or 3 h (for cryoprotection) at 4°C in the same fixative.
Brains were then cut coronally or sagittally and prepared
for paraffin embedding or cryoprotection. For paraffin
embedding, tissues were dehydrated in a graded series
of alcohols, cleared with Hemo-De (a Xylene substitu-
tive, FALMA, Tokyo, Japan), embedded in Paraplast
(Sigma, St. Louis, MO, USA), and sectioned at 3 μm. After
deparaffinization and rehydration, endogenous peroxidase
activity was blocked by 0.03% H2O2 methanol solution for
10 min. Sections were then incubated for 1 h at room
temperature in blocking solution containing 2% bovine
serum albumin (Jackson ImmunoResearch, West Grove,
PA, USA) in 0.01 M PBS with 0.02% Tween-20, followed
by incubation with primary antibodies diluted in blocking
solution at 4°C overnight (anti-URAT1 antibody, 1:5000).
Immunostaining was visualized with EnVision™ Systems
and DAB+, Liquid (Dako Japan, Tokyo Japan). To prepare
cryostat sections (12 μm), post-fixed brains were cryopro-
tected in 15% sucrose (wt/vol) in PBS for 48 h at 4°C,
embedded in Tissue-Tek OCT compound (Sakura Finetek
Japan, Tokyo, Japan), and frozen on dry ice. Cryostat sections
were fixed in methanol (−20°C, 30 min) and acetone(4°C, 10 min), incubated for 1 h at room temperature in
blocking solution containing 5% normal goat serum
(Cedarlane, Ontario, Canada) in 0.01 M PBS with 0.1%
Triton X-100, followed by incubation with primary anti-
bodies diluted in blocking solution at 4°C overnight. The
following antibodies were used for double staining: anti-
URAT1, 1:1000; anti-acetylated-α-tubulin (6-11B-1,
IgG2b, Sigma), 1:500. Sections were then incubated
with Alexa 488- or Alexa 594-conjugated secondary anti-
bodies (Life Technologies, Tokyo, Japan) for 1 h at room
temperature and mounted with Vectashield containing
DAPI (Vector Laboratories, Burlingame, CA, USA).
Image acquisition
DAB-stained sections were scanned with a NanoZoomer
2.0-HT slide scanner (Hamamatsu Photonics, Hamamatsu,
Japan). For immunofluorescence experiments, single-plane
images were captured using a Nikon A1 confocal micro-
scope (Nikon, Tokyo, Japan) with identical settings.
Results
Distribution of URAT1 in mouse brain
To investigate the distribution of URAT1 in the mouse
brain, we performed immunohistochemistry upon adult
mouse brain paraffin coronal sections by using a rabbit poly-
clonal anti-mouse URAT1 antibody [17]. Strong URAT1
immunoreactivity was detected in ependymal cells lining the
lateral ventricle (Figure 1A and B), dorsal third ventricle
(Figure 1C), ventral third ventricle (Figure 1D), aqueduct
(Figure 1E) and fourth ventricle (Figure 1F). These patterns
of immunoreactivity were not observed in sections from the
URAT1 knockout mice (Figure 1G–L). Weaker immuno-
staining in the brain parenchyma, and the choroid plexus
of the lateral and dorsal third ventricles, appeared to be
non-specific, since similar staining was observed in sections
from the knockout mice (Figure 1).
Ependymal cells form an epithelial layer that lines the
cerebral ventricles and function as a barrier between the
cerebrospinal fluid and the brain parenchyma. Morphologi-
cally, these cells possess cilia and microvilli on their apical
surfaces. At higher magnification, dense URAT1 positive
signals were detected in cilia-like protrusions (Figure 1A–F,
lower panels). URAT1 localization along the ventral third
ventricle was restricted to the ependymal cells that line the
upper part of the ventral third ventricle and could not be
observed in the non-ciliated tanycytes, which are located in
the lower part of the ventral third ventricle (Figure 1D).
URAT1-distribution in the ventricles was also exa-
mined in sagittal sections, showing continuous expression
in the lateral ventricle (Figure 1M), dorsal third ventricle
(Figure 1M), aqueduct (Figure 1N and O) and fourth ven-
tricle (Figure 1N). These results suggest that URAT1 is
expressed in ciliated-ependymal cells in the ventricular
system of the mouse brain.
Figure 1 Distribution of URAT1 in mouse brain. Paraffin sections from nine-week-old WT (A–F, coronal section; M–O, sagittal section) and
URAT1 KO (G–L, coronal section) mice were stained with a polyclonal antibody to URAT1 (anti-URAT1 antibody) and counterstained with
hematoxylin. Red squares in the diagrams indicate the region of the images while the lower panels show magnified images around the
ependymal cells (represented as dotted squares in the upper panels). Images (B–D), (H–J) or (M–N) were obtained from the same sections,
respectively. Scale bars, 200 μm and 10 μm in top and bottom row of (L), respectively; 200 μm in (M–O). LV, lateral ventricle; V3V, ventral third
ventricle; D3V, dorsal third ventricle, AQ, aqueduct; 4V, fourth ventricle.
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Interestingly, URAT1 immunoreactivity in the aqueduct
was prominent compared to the other ventricular regions
(Figure 1E,N,O). To confirm this point, we performed im-
munofluorescence staining of frozen sections using the
same anti-URAT1 antibody. Similar to the results gleanedfrom paraffin section immunohistochemistry, intense im-
munoreactivity was distributed in the ependymal cells of
multiple ventricles, but not at the choroid plexus or in the
brain parenchyma (Figure 2A–F). In the ventral third ven-
tricle, URAT1-positive signals were restricted to the upper
part of the ventral third ventricle and not detected in
Figure 2 Expression levels of URAT1 differ between ventricles. (A–F) Frozen coronal sections from nine-week-old WT mice were stained
with anti-URAT1 (red) and DAPI (blue) and imaged by confocal microscopy. Scale bar, 200 μm.
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(Figure 2D). Within the ventricular system, the strongest
signal was observed in the aqueduct (Figure 2E), indicating
that expression levels of URAT1 differ between ventricles.
URAT1 localizes to the apical surface, including the cilia
of ependymal cells
Finally, we performed double-immunostaining using an
anti-URAT1 antibody and anti-acetylated-α-tubulin anti-
body as a marker for cilia (Figure 3). At high magnification,
URAT1 localized to the apical but not to the basolateral
membrane of the ependymal cells, which largely co-exist
with acetylated-α-tubulin. The absence of URAT1 in the
cilia did not affect the localization of acetylated-α-tubulin,
indicating that cilia morphology is intact in the knockout
mouse. Reminiscent of the URAT1 expression at the apical
brush-border membrane of the renal tubular cells, URAT1
localized to the apical membrane including the cilia of
ependymal cells.
Discussion
In the present study, we suggest that the urate transporter
URAT1 is involved in UA transport in the ventricular
ependymal cells of the mouse brain. Using immunohisto-
chemistry, we showed that URAT1 is expressed on cilia
and the apical surface of ependymal cells surrounding theventricles, and the absence of such staining was confirmed
in URAT1 knockout mice. Although URAT1 expression
in brain tissues such as brain capillaries, choroid plexus
[14], cultured dopaminergic cell lines and astrocytes [18]
has been demonstrated by immunoblot analyses, we could
not observe comparable expression of URAT1 by immu-
nohistochemical analyses in such regions as we did in
ependymal cells. Weaker immunostaining in the brain
parenchyma and the choroid plexus were observed in sec-
tions from both wild type and knockout mice. Therefore,
the band identified by immunoblotting in earlier studies
might represent a non-specific binding to a protein other
than URAT1. Moreover, earlier studies failed to check
whether ependymal cells may have contaminated the brain
capillary, choroid plexus or astrocyte samples which were
used for immunoblotting. Thus, the expression of URAT1
protein in brain capillaries, choroid plexus or astrocytes has
not been verified completely. To our knowledge, this is the
first report to demonstrate urate transporter localization in
ventricular ependymal cells.
Ependymal cells are single-layered ciliated epithelial cells
lining the ventricular surface of the central nervous sys-
tem, and act as the brain-CSF interface. This site is re-
sponsible for the exchange of substances between CSF and
extracellular fluid in the neuropile [19]. Since URAT1
transports UA via a mechanism involving the exchange of
Figure 3 URAT1 localizes at the apical surface of ependymal cells. Frozen coronal sections from nine-week-old WT and URAT1 KO mice
were stained with anti-acetylated-α-tubulin antibody (green), anti-URAT1 antibody (red) and DAPI (blue). The cilia of the ependymal cells lining
the D3V were visualized by anti-acetylated-α-tubulin antibody as a cilia marker. Scale bar, 20 μm.
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the CSF is absorbed intracellularly by ependymal cells in
the presence of an outwardly-directed lactate gradient.
There are two conceivable possibilities for the formation of
this lactate gradient. As in the renal tubular cells, a lactate
gradient can be formed by the sodium-coupled monocar-
boxylate transporters SMCT1 and SMCT2, which collect-
ively facilitate the reabsorption of UA via URAT1 [20].
However, the expression of SMCT1 and SMCT2 have only
been demonstrated in neurons and Muller glial cells, re-
spectively [21,22], and the expression and possible involve-
ment of SMCTs in ependymal cells remains unknown.
Alternatively, the difference in basal lactate concentration
between CSF and ependymal cells may be important. Both
human and rat data show that lactate concentration is
higher in brain ECF (2–5 mM) compared to that in blood
(1–2 mM) [23]. In humans, levels of CSF lactate range from
2.0 to 2.7 mM [24]. Since other lactate transporter proteins,
referred to as MCT1, MCT2 and MCT4 (monocarboxylate
transporter 1, 2 and 4), have been identified in ependymal
cells, probably on the basolateral side [25-29], the lactate
levels in ependymal cells may be equivalent to those of
brain parenchyma, and thus likely to be higher than CSF
lactate. Further analysis regarding the formation of a lactate
gradient would be essential in understanding the UA
transporting function of URAT1 in ependymal cells.
One outstanding question is how UA might function fol-
lowing incorporation into ependymal cells. One possibility
is that intracellular UA may act as an antioxidant and main-
tain the redox state of ependymal cells. These cells have
been shown to contain high levels of glutathione (GSH)
[30], a major antioxidant in the CNS, suggesting a need for
antioxidant mechanisms. Intriguingly, in the ventral third
ventricle, we observed positive staining of URAT1 only in
ciliated ependymal cells, but not in the tanycytes, which arenon-ciliated cells lining the lower part of the ventral third
ventricle. Intracellular uptake of UA may thus be impor-
tant for the specific function of ciliated-ependymal cells
such as ciliary beating, an essential mechanism for proper
CSF flow [31].
Another possibility is that UA incorporated into the
ependymal cells is further transported into the brain paren-
chyma. The fact that we detected strong URAT1 expres-
sion in ependymal cells may indicate a novel trans-cellular
transport mechanism for UA across ependymal cells. This
is reminiscent of the UA transport system in the proximal
renal tubular cells, in which UA is reabsorbed by URAT1
in the apical membrane and effluxed by URATv1/Glut9 in
the basolateral membrane. If urate efflux transporters exist
on the basolateral side of ependymal cells, then it is pos-
sible that CSF-derived UA could pass through the brain
parenchyma and be finally incorporated into neurons and/
or astrocytes. One could speculate that UA transport may
occur at the blood–brain barrier (BBB). However, the
provision of UA from blood to brain parenchyma seems
unlikely, since at this point, immunohistochemical data
indicate that the urate efflux transporter ABCG2 is the sole
UA transporter localized on the luminal side of brain capil-
laries [13]. Collectively, the URAT1-mediated transport of
UA via ependymal cells represents a promising candidate
for a key molecule involved in the regulation of UA homeo-
stasis in the brain.
Based on epidemiological and clinical data showing that
higher UA levels are associated with reduced risk and
slower progression of PD, UA-elevating strategies have
emerged as a potential therapy for PD [5]. Furthermore, at-
tenuated neurodegeneration has been demonstrated in ani-
mal models of PD which showed increased levels of UA in
response to the genetic manipulation of the UA-degrading
enzyme, urate oxidase [3], or by UA injection [4], providing
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temic elevation of UA is clearly pathogenic and the
benefit-risk ratio of a therapeutic UA-elevating strategy re-
mains uncertain. If the UA transport activity of URAT1 in
ependymal cells is critical for the provision of UA to the
brain, then the selective facilitation of URAT1 activity,
and/or up-regulation of ependymal URAT1 expression
in the brain, may be a beneficial strategy for developing
UA-based therapy against neurodegenerative diseases.
Conclusions
Our data suggests that the urate transporter URAT1 is
expressed on cilia and the apical surface of ventricular
ependymal cells in mouse brain. Ependymal URAT1 may
thus be involved in a novel UA transport mechanism be-
tween CSF and brain parenchyma.
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